Translation Program

Translation Program


The Translation Program brings together researchers from other DERC Research Programs investigating fundamental processes leading to diabetes in humans with those translating preclinical findings to improvements in diabetes treatment. One strong component of the Translation Program includes researchers involved in the development of treatments for Type 1 diabetes. Researchers within the Translation Program also study the processes directly leading to diabetes in its most pertinent model organism, humans. These studies incorporate the ability to use a new generation of genomic and metabolic tools to investigate the underlying causes of disease and as well as the modes of action of drug therapies within the patient population. Human studies of the genetic and environmental factors affecting diabetes development and treatment represent another focus of the Translation Program. Thus, the Translation Program translates basic research to human treatment (“bench to bedside”) and studies humans to discover the most pertinent basic research areas (“bedside to bench”).

Translation Program Members

Ahituv, Nadav
Anderson, Mark
Bluestone, Jeffrey
Fisher, Lawrence
Giacomini, Kathleen
Gitelman, Stephen
Grunfeld, Carl
Kanaya, Alka
Krauss, Ronald
Lainer, Lewis
Masharani, Umesh
Mulligan, Kathleen
Posselt, Andrew
Rao, Madhu
Risch, Neil
Savic, Rada
Sayre, Peter
Schafer, Anne
Schillinger, Dean
Seligman, Hilary
Stock, Peter
Vincenti, Flavio
Vaisse, Christian
Wojciechowski, David

 

CENTER MEMBERS ARE REMINDED TO ACKNOWLEDGE DERC CENTER GRANT (P30 DK063720) CONTRIBUTIONS WITH ‘THIS RESEARCH WAS SUPPORTED BY GRANTS X, Y FROM NIH P30 DK063720'.